In the DHCG Disruptive Dose interview with Mark Bard, RJ Lewis, Founder & CEO of eHealthcare Solutions, delivers a stark assessment of how artificial intelligence is reshaping medical publishing—and by extension, the downstream impact on pharma content strategy. For Pharma Marketing Networks readers, his observations carry urgency: fundamental publishing economics are under pressure, and the industry must respond.
Watch the interview now:
In this episode of Disruptive Dose
Lewis begins by reframing how physicians search for medical information. He argues that search is transforming into an “answer engine,” a dynamic in which AI systems directly generate responses to clinician queries. In his view, this shift is beneficial for end users but presents an existential threat to traditional medical publishers. He underscores the magnitude of the impact: web traffic to some commercial medical publishing sites has plunged by 40–50 %, a dramatic decline that jeopardizes the ad-revenue models underpinning content creation and research funding. Lewis draws a comparison to the news media industry, suggesting that medical publishing could be similarly “gutted” if it fails to adapt. Given the erosion of traffic and advertising income, Lewis argues that publishers must pursue new economic models. One proposed path involves charging users—or LLMs themselves—for subscriptions to access “unique, high-value” content. He raises the possibility that aggregators could emerge in the medical space, likening this to how streaming platforms changed music distribution. In his words, an “Open Evidence” platform might become the “Spotify” of medical research. In sum, he suggests that to preserve value, publishers must protect and monetize distinctive content—otherwise traditional models are at risk of collapse. Why should Pharma Marketers care about this disruption in healthcare publishing? Several implications emerge for pharma marketers teams: While Lewis does not prescribe detailed Pharma Marketing tactics in the interview, his observations highlight several strategic inflection points: RJ Lewis’ perspective makes one point crystal clear: AI is not a distant disruptor—it is already reshaping the economics of medical publishing. With traffic and ad revenues collapsing, traditional models face existential risk. For pharma marketers overseeing brand’s websites, this moment demands vigilance and adaptability. Unique, high-value content, smart licensing strategies, and close attention to emerging platforms will determine who thrives in this new environment. Those who move early will have the best chance to secure influence in the evolving landscape of evidence access and physician engagement. Read more Pharma Marketing articles now. AI as “Answer Engine” and Existential Risk to Publishers
New Business Models: Charging for Access & Aggregation
Key Implications for Pharma Marketers
As AI-driven answer engines bypass traditional web traffic models, investment in SEO, content marketing, or journal sponsorships may deliver lower returns.
“Unique, high-value” content is the kind of asset worth monetizing. Commoditized publications may suffer under new dynamics.
The concept of “Open Evidence” platforms suggests that evidence might increasingly be centralized under aggregator systems that license or curate content, rather than be accessed piecemeal via publisher sites.
If AI systems or aggregators become intermediaries, negotiating content access and licensing could become a core capability for publishing or pharma-owned content assets.What Pharma Should Watch
Companies should closely track whether they begin to see declines in publisher site traffic or disruptions in advertising returns.
Assets with differentiated insight or data may retain value; generic clinical summaries may struggle.
As aggregators or AI platforms emerge, being part of licensing discussions might help secure visibility of pharma-supported evidence.
If one or more aggregator platforms take off, pharma should assess how to position its evidence in those systems.Conclusion
